메뉴 건너뛰기




Volumn 26, Issue 6, 2014, Pages 581-587

Biosimilars in the therapy of inflammatory bowel diseases

Author keywords

Biosimilars; Crohn's disease; immunogenicity; inflammatory bowel diseases; infliximab; safety; ulcerative colitis

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; BIOSIMILAR AGENT; CETUXIMAB; CT P 13; EPITOPE; ETANERCEPT; GROWTH FACTOR; INFLIXIMAB; MONOCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR ALPHA;

EID: 84900459730     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000098     Document Type: Review
Times cited : (40)

References (60)
  • 4
    • 32044451548 scopus 로고    scopus 로고
    • Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn?s disea se: The CLASSIC-I trial
    • Hanauer SB, SandbornWJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn?s disea se: the CLASSIC-I trial. Gastroenterology 2006; 130:323-333
    • (2006) Gastroenterology , vol.130 , pp. 323-333
    • Hanauer, S.B.1    Sandborn, W.J.2    Rutgeerts, P.3    Fedorak, R.N.4    Lukas, M.5    Mac Intosh, D.6
  • 5
    • 84856163835 scopus 로고    scopus 로고
    • Adalimumab induces and maintains clinical remi ssion in patients with moderate-to-severe ulcerative colitis
    • e1-e3
    • Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D?Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remi ssion in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142:257- 265, e1-e3
    • (2012) Gastroenterology , vol.142 , pp. 257-265
    • Sandborn, W.J.1    Van Assche, G.2    Reinisch, W.3    Colombel, J.F.4    Dhaens, G.5    Wolf, D.C.6
  • 8
    • 0033842357 scopus 로고    scopus 로고
    • Use of infliximab in the treatment of Crohn?s disease in children and adolescents
    • Hyams JS, Markowitz J,Wyllie R. Use of infliximab in the treatment of Crohn?s disease in children and adolescents. J Pediatr 2000; 137:192-196
    • (2000) J Pediatr , vol.137 , pp. 192-196
    • Hyams, J.S.1    Markowitz, J.2    Wyllie, R.3
  • 9
    • 84870293844 scopus 로고    scopus 로고
    • Ciclosporin versus infliximab in pati ents with severe ulcerative colitis refractory to intravenous steroids: A parallel, open-label randomised controlled trial
    • Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Ciclosporin versus infliximab in pati ents with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380:1909- 1915
    • (2012) Lancet , vol.380 , pp. 1909-1915
    • Laharie, D.1    Bourreille, A.2    Branche, J.3    Allez, M.4    Bouhnik, Y.5    Filippi, J.6
  • 10
    • 79959479569 scopus 로고    scopus 로고
    • Use of biologics in rheumatoid arthritis: Current and emerging paradigms of care
    • Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 2011; 33:679-707
    • (2011) Clin Ther , vol.33 , pp. 679-707
    • Curtis, J.R.1    Singh, J.A.2
  • 11
    • 84878536093 scopus 로고    scopus 로고
    • Development and regulation of biosimilars: Current status and future challenges
    • Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: current status and future challenges. BioDrugs 2013; 27:203-211
    • (2013) BioDrugs , vol.27 , pp. 203-211
    • Tsiftsoglou, A.S.1    Ruiz, S.2    Schneider, C.K.3
  • 14
    • 84874173298 scopus 로고    scopus 로고
    • European perspective on biosimilars
    • Wadhwa M, Thorpe R. European perspective on biosimilars. Bioanalysis 2013; 5:521-524
    • (2013) Bioanalysis , vol.5 , pp. 521-524
    • Wadhwa, M.1    Thorpe, R.2
  • 15
    • 84900410623 scopus 로고    scopus 로고
    • European Medicinal Agency (EMA). Available at Accessed 13 O ctober
    • European Medicinal Agency (EMA). EMA procedural advice for biosimilar applications. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Regulatory-and-procedural-guideline/2009/10/WC500004018.pdf. [Accessed 13 O ctober 2013]
    • (2013) EMA procedural advice for biosimilar applications
  • 16
    • 84900416820 scopus 로고    scopus 로고
    • Title VII-improving access to innovative medical therapies
    • US Food and Drug Administration Available at Accessed 20 November
    • US Food and Drug Administration. Title VII-improving access to innovative medical therapies. ?Biologics Price Competition and Innovation Act of 2009?. Available at: http://www.fda.gov/download s/Drugs/GuidanceCompliance RegulatoryInformation/UCM216146.pdf. [Accessed 20 November 2013]
    • (2013) ?Biologics Price Competition and Innovation Act of 2009?
  • 17
    • 84900461266 scopus 로고    scopus 로고
    • US Food and Drug Administration Available at Accessed 22 November
    • US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Available at: http://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM291128.pdf. [Accessed 22 November 2013]
    • (2013) Scientific Considerations in Demonstrating Biosimilarity to A Reference Product
  • 18
    • 51349137409 scopus 로고    scopus 로고
    • Toward biosimilar monoclonal antibodies
    • Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985-990
    • (2008) Nat Biotechnol , vol.26 , pp. 985-990
    • Schneider, C.K.1    Kalinke, U.2
  • 21
    • 84883880492 scopus 로고    scopus 로고
    • Approval of the first biosimilar antibodies in Europe: A major landmark for the biopharmaceutical industry
    • Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013; 5:621-623
    • (2013) MAbs , vol.5 , pp. 621-623
    • Beck, A.1    Reichert, J.M.2
  • 22
    • 84883879484 scopus 로고    scopus 로고
    • Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab
    • Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2 013; 27:495-507
    • (2013) BioDrugs , vol.27 , pp. 495-507
    • Visser, J.1    Feuerstein, I.2    Stangler, T.3    Schmiederer, T.4    Fritsch, C.5    Schiestl, M.6
  • 23
    • 84860619510 scopus 로고    scopus 로고
    • Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrels): A double-bli nd, single-dose, crossover study in healthy volunteers
    • Yi S,Kim SE,Park M-K,Yoon SH,Cho J-Y,Lim KS ,et al. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrels): a double-bli nd, single-dose, crossover study in healthy volunteers, BioDrugs, 2012,26, 177-184.
    • (2012) BioDrugs , vol.26 , pp. 177-184
    • Yi, S.1    Kim, S.E.2    Park, M.-K.3    Yoon, S.H.4    Cho, J.-Y.5    Lim, K.S.6
  • 24
    • 83455201580 scopus 로고    scopus 로고
    • Comparative pharmacokinetics and tolerabi lity of branded etanercept (25 mg) and its biosimilar (25 mg): A randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers
    • Gu N, Yi S, Kim T-E, Kim J, Shin S-G, Jang I-J, et al. Comparative pharmacokinetics and tolerabi lity of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. Clin Ther 2011; 33:2029-2037
    • (2011) Clin Ther , vol.33 , pp. 2029-2037
    • Gu, N.1    Yi, S.2    Kim, T.-E.3    Kim, J.4    Shin, S.-G.5    Jang, I.-J.6
  • 25
    • 84900436651 scopus 로고    scopus 로고
    • Available at Accessed 5 March
    • Merck. 2013 Mer ck annual report. Available at: http://www.merck.com/ investors/financials/annual-reports/. [Accessed 5 March 2014]
    • (2014) Merck. 2013 Merck Annual Report
  • 26
    • 70450195261 scopus 로고    scopus 로고
    • Controlling the cost of innovative cancer therapeutics
    • Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol 2009; 6:550-552
    • (2009) Nat Rev Clin Oncol , vol.6 , pp. 550-552
    • Malik, N.N.1
  • 27
    • 84861842454 scopus 로고    scopus 로고
    • Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry
    • Beck A, Sanglier-Cianfé rani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637-4646
    • (2012) Anal Chem , vol.84 , pp. 4637-4646
    • Beck, A.1    Sanglier-Cianferani, S.2    Van Dorsselaer, A.3
  • 28
    • 62949147825 scopus 로고    scopus 로고
    • EMA statement on Inflectra Available at Accessed 13 October
    • European Medicinal Agency (EMA). EMA statement on Inflectra. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion- Initial-authorisation/human/002778/WC500144831.pdf. [Accessed 13 October 2013]
    • (2013) European Medicinal Agency (EMA)
  • 29
    • 0015791561 scopus 로고
    • Human-mouse somatic cell hybrid clone secreting immunoglobulins of both parental types
    • Schwaber J, Cohen EP. Human-mouse somatic cell hybrid clone secreting immunoglobulins of both parental types. Nature 1973; 244:444-447
    • (1973) Nature , vol.244 , pp. 444-447
    • Schwaber, J.1    Cohen, E.P.2
  • 30
    • 84883752718 scopus 로고    scopus 로고
    • A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in pa tients with active rheumatoid arthritis: The PLANETRA study
    • Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in pa tients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72:1613-1620
    • (2013) Ann Rheum Dis , vol.72 , pp. 1613-1620
    • Yoo, D.H.1    Hrycaj, P.2    Miranda, P.3    Ramiterre, E.4    Piotrowski, M.5    Shevchuk, S.6
  • 31
    • 84883746909 scopus 로고    scopus 로고
    • A randomised, dou ble-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study
    • Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, dou ble-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72:160 5-1612
    • (2013) Ann Rheum Dis , vol.72 , pp. 1605-1612
    • Park, W.1    Hrycaj, P.2    Jeka, S.3    Kovalenko, V.4    Lysenko, G.5    Miranda, P.6
  • 32
    • 84875477617 scopus 로고    scopus 로고
    • The continuum of comparability extends to biosimilarity: How much is enough and what clinical data are necessary
    • McCamish M, Woollett G. The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary Clin Pharmacol Ther 2013; 93:315-317
    • (2013) Clin Pharmacol Ther , vol.93 , pp. 315-317
    • Mc Camish, M.1    Woollett, G.2
  • 37
    • 33748921915 scopus 로고    scopus 로고
    • Biophysical comparability of the same protein from different manufacturers: A case study using epoetin alfa fr om Epogen and Eprex
    • Deechongkit S, Aoki KH, Park SS, Kerwin BA. Biophysical comparability of the same protein from different manufacturers: a case study using epoetin alfa fr om Epogen and Eprex. J Pharm Sci 2006; 95:1931-1943
    • (2006) J Pharm Sci , vol.95 , pp. 1931-1943
    • Deechongkit, S.1    Aoki, K.H.2    Park, S.S.3    Kerwin, B.A.4
  • 38
    • 84884901120 scopus 로고    scopus 로고
    • Epoetin biosimilars in Europe: Five years on
    • Mikhail A, Farouk M. Epoetin biosimilars in Europe: five years on. Adv Ther 2013; 30:28-40
    • (2013) Adv Ther , vol.30 , pp. 28-40
    • Mikhail, A.1    Farouk, M.2
  • 39
    • 79953154625 scopus 로고    scopus 로고
    • Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: A randomized prospective study
    • Lissy M, Ode M, Roth K. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. Drugs R D 2011; 11:61-7 5
    • (2011) Drugs RD , vol.11 , pp. 61-75
    • Lissy, M.1    Ode, M.2    Roth, K.3
  • 40
    • 41149131276 scopus 로고    scopus 로고
    • Epoetin zeta study group comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia tr eatment
    • Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R. Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia tr eatment. Curr Med Res Opin 2008; 24:625-637
    • (2008) Curr Med Res Opin , vol.24 , pp. 625-637
    • Wizemann, V.1    Rutkowski, B.2    Baldamus, C.3    Scigalla, P.4    Koytchev, R.5
  • 41
    • 69949150756 scopus 로고    scopus 로고
    • Long-term safety and tolerability of epoetin zeta, administered in travenously, for maintenance treatment of renal anemia
    • Baldamus C, Krivoshiev S,Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A. Long-term safety and tolerability of epoetin zeta, administered in travenously, for maintenance treatment of renal anemia. Adv Ther 2008; 25:1215-1228
    • (2008) Adv Ther , vol.25 , pp. 1215-1228
    • Baldamus, C.1    Krivoshiev, S.2    Wolf-Pflugmann, M.3    Siebert-Weigel, M.4    Koytchev, R.5    Bronn, A.6
  • 42
    • 44349139462 scopus 로고    scopus 로고
    • Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia
    • Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 2008; 24:1407-1415
    • (2008) Curr Med Res Opin , vol.24 , pp. 1407-1415
    • Krivoshiev, S.1    Todorov, V.V.2    Manitius, J.3    Czekalski, S.4    Scigalla, P.5    Koytchev, R.6
  • 43
    • 79251633136 scopus 로고    scopus 로고
    • Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis
    • Wiecek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: posthoc analysis. Adv Ther 2010; 27:941-952
    • (2010) Adv Ther , vol.27 , pp. 941-952
    • Wiecek, A.1    Ahmed, I.2    Scigalla, P.3    Koytchev, R.4
  • 45
    • 78650543555 scopus 로고    scopus 로고
    • Impact of product-related factors on immunogenicity of biotherapeutics
    • Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2011; 100:354-387
    • (2011) J Pharm Sci , vol.100 , pp. 354-387
    • Singh, S.K.1
  • 47
    • 78650515906 scopus 로고    scopus 로고
    • 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    • Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47:8-32
    • (2011) Eur J Cancer , vol.47 , pp. 8-32
    • Aapro, M.S.1    Bohlius, J.2    Cameron, D.A.3    Dal Lago, L.4    Donnelly, J.P.5    Kearney, N.6
  • 49
    • 77954653769 scopus 로고    scopus 로고
    • Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator
    • Jiang H,Wu S-L, Karger BL, H ancock WS. Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator. Anal Chem 2010; 82:6154-6162
    • (2010) Anal Chem , vol.82 , pp. 6154-6162
    • Jiang Hwu, S.-L.1    Karger, B.L.2    Hancock, W.S.3
  • 51
    • 19044397056 scopus 로고    scopus 로고
    • Epoetinassociated pure red cell aplasia in patients with chronic kidney disease: Solving the mystery
    • Boven K, Knight J, Bader F, Rossert J, Eckardt K-U, Casadevall N. Epoetinassociated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 2005; 20 (Suppl 3):iii33-iii40
    • (2005) Nephrol Dial Transplant , vol.20 , Issue.SUPPL.3
    • Boven, K.1    Knight, J.2    Bader, F.3    Rossert, J.4    Eckardt, K.-U.5    Casadevall, N.6
  • 52
    • 77957723026 scopus 로고    scopus 로고
    • Biosimilar epoetins and other 'follow-on' biologics: Update on the European experiences
    • Jelkmann W. Biosimilar epoetins and other ?follow-on? biologics: update on the European experiences. Am J Hematol 2010; 85:771-780
    • (2010) Am J Hematol , vol.85 , pp. 771-780
    • Jelkmann, W.1
  • 53
    • 84862644490 scopus 로고    scopus 로고
    • Tungsteninduced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity
    • Seidl A, Hainzl O, Richter M, Fischer R, Bö hm S, Deutel B, et al. Tungsteninduced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 2012; 29:1454-1467
    • (2012) Pharm Res , vol.29 , pp. 1454-1467
    • Seidl, A.1    Hainzl, O.2    Richter, M.3    Fischer, R.4    Bohm, S.5    Deutel, B.6
  • 55
    • 84885871577 scopus 로고    scopus 로고
    • Biosimilar filgrastim mobilizes haematopoietic stem cells in healthy volunteer donors with expected efficiency and typical acute adverse effects: Interim results of a postauthorizatio n safety study
    • Becker P, Brauninger S, Bialleck H. Biosimilar filgrastim mobilizes haematopoietic stem cells in healthy volunteer donors with expected efficiency and typical acute adverse effects: interim results of a postauthorizatio n safety study. Bone Marrow Transplant 2013; 48:O177
    • (2013) Bone Marrow Transplant , vol.48
    • Becker, P.1    Brauninger, S.2    Bialleck, H.3
  • 56
    • 84878624235 scopus 로고    scopus 로고
    • Governing Board and Operational Board of ECCO. ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
    • Danese S, Gomollon F; Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013; 7:586-589
    • (2013) J Crohns Colitis , vol.7 , pp. 586-589
    • Danese, S.1    Gomollon, F.2
  • 57
    • 84878532312 scopus 로고    scopus 로고
    • Joint position statement by Spanish Society of gastroenterology and spanish society of pharmacology on biosimilar therapy for inflamm atory bowel disease
    • Argü elles-Arias F, Barreiro-de-Acosta M, Carballo F, Hinojosa J, Tejerina T. Joint position statement by Spanish Society of Gastroenterology and Spanish Society of Pharmacology on biosimilar therapy for inflamm atory bowel disease. Rev Esp Enferm Dig 2013; 105:37-43
    • (2013) Rev Esp Enferm Dig , vol.105 , pp. 37-43
    • Arguelles-Arias, F.1    Barreiro-De-Acosta, M.2    Carballo, F.3    Hinojosa, J.4    Tejerina, T.5
  • 58
    • 0034754477 scopus 로고    scopus 로고
    • Etanercept for active Crohn?s disease: A randomized, double -blind, placebocontrolled trial
    • Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn?s disease: a randomized, double -blind, placebocontrolled trial. Gastroenterology 2001; 121:1088-1094
    • (2001) Gastroenterology , vol.121 , pp. 1088-1094
    • Sandborn, W.J.1    Hanauer, S.B.2    Katz, S.3    Safdi, M.4    Wolf, D.G.5    Baerg, R.D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.